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Aims To evaluate the anti-anginal and anti-ischaemic efﬁcacy of the selective If current inhibitor ivabradine in patients with
chronic stable angina pectoris receiving beta-blocker therapy.
Methods
and results
In this double-blinded trial, 889 patients with stable angina receiving atenolol 50 mg/day were randomized to receive
ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months, or placebo. Patients underwent
treadmill exercise tests at the trough of drug activity using the standard Bruce protocol for randomization and at 2
and 4 months. Total exercise duration at 4 months increased by 24.3+65.3 s in the ivabradine group, compared with
7.7+63.8 s with placebo (P , 0.001). Ivabradine was superior to placebo for all exercise test criteria at 4 months
(P , 0.001 for all) and 2 months (P-values between ,0.001 and 0.018). Ivabradine in combination with atenolol was
well tolerated. Only 1.1% of patients withdrew owing to sinus bradycardia in the ivabradine group.
Conclusion The combination of ivabradine 7.5 mg b.i.d. and atenolol at the commonly used dosage in clinical practice in patients
with chronic stable angina pectoris produced additional efﬁcacy with no untoward effect on safety or tolerability.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Angina pectoris is typically caused by myocardial ischaemia owing
to an imbalance between myocardial perfusion and oxygen
demand. Elevated heart rate increases myocardial oxygen
demand and limits tissue perfusion, the latter by reducing the dur-
ation of diastole during which most myocardial perfusion occurs.
Long-term prognosis in patients with chronic stable angina pectoris
is favourable
1 and medical and interventional therapies show
similar beneﬁt.
2,3 Thus, current treatment guidelines advocate an
initial approach with medical therapy.
4–6 Beta-blockers reduce
myocardial ischaemia and prevent angina pectoris largely by lower-
ing heart rate and are recommended as an initial therapy for stable
angina pectoris, unless contraindicated.
6–8
In modern clinical practice, however, many patients with stable
angina pectoris require treatment with more than one anti-anginal
drug, in addition to short-acting nitrates.
6,9 Ivabradine is a pure
heart rate-lowering agent that acts by inhibiting If, an important
ionic current involved in the pacemaker activity in cells of the
sino-atrial node.
10 Ivabradine reduces the slope of spontaneous
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and during exercise. Given as monotherapy (with short-acting
nitrates allowed as required), ivabradine has demonstrated anti-
ischaemic and anti-anginal efﬁcacy in randomized trials in patients
with chronic stable angina pectoris when compared with
placebo
11 and has been shown to be non-inferior to atenolol
12
or amlodipine.
13 The drug has been recommended for the
medical management of patients with stable angina pectoris who
are intolerant of beta-blockers or in whom these agents are
contraindicated.
6
The primary purpose of the present study was to evaluate the
anti-ischaemic and anti-anginal efﬁcacy of ivabradine, relative to
placebo, when given to patients with chronic stable angina pectoris
receiving beta-blocker therapy.
Methods
Study population
Eligible patients were male and female outpatients aged  18 and  75
years, with a history of chronic angina pectoris on effort for  3
months before study entry, and evidence of coronary artery disease
documented by one or more of the following criteria: myocardial
infarction  3 months before study entry; percutaneous coronary
angioplasty  6 months or coronary artery bypass surgery  3
months before study entry; coronary angiography showing  50%
diameter stenosis of one or more major coronary arteries; positive
scintigraphic test showing exercise-induced reversible myocardial
ischaemia; or a positive stress echocardiography showing regional
wall motion abnormality and failure of normal rise in left ventricular
ejection fraction with exercise. Other inclusion criteria included
sinus rhythm at the pre-selection visit, current treatment with atenolol
50 mg o.d., or another beta-blocker at equivalent doses for at least
3 months. Patients had to show three positive symptom-limited
exercise tolerance tests (ETTs) with the standard Bruce protocol
during the run-in period and stability of ETT results between the
second and third tests.
Exclusion criteria included: heart rate ,60 b.p.m. on ECG at rest;
signiﬁcant heart disease other than coronary artery disease; angina
pectoris at rest, unstable angina pectoris, Prinzmetal or microvascular
angina; severe heart failure symptoms (New York Heart Association
class III or IV); symptomatic hypotension or uncontrolled hypertension
(resting systolic blood pressure .180 mmHg or diastolic blood
pressure .100 mmHg); chronic or paroxysmal atrial ﬁbrillation
presentatthepre-selectionvisit;atrialﬂutter;apacemakerorimplanted
deﬁbrillator; any condition that interferes with the ability to perform or
interpret ETT (e.g. physical incapacity, Wolff–Parkinson–White syn-
drome,completeleftbundlebranchblock,leftventricularhypertrophy);
contraindication or intolerance to atenolol; previous treatment
with atenolol at a dose .50 mg o.d., or another beta-blocker at a
corresponding dose; recent treatment with amiodarone (,3 months)
or bepridil (,7 days); known severe renal failure, liver function test
abnormality, or known electrolyte disorder; anaemia (blood haemo-
globin ,110 g/Lor6.8 mmol/L);andthyroiddisordersunlesscontrolled
by thyroxine for  3 months.
Written informed consent was obtained from all patients. The study
was performed in accordance with the ethical principles stated in the
Declaration of Helsinki, 1964, as revised in Washington, 2002. The
study was approved by the institutional review board of each partici-
pating centre.
Study design
This was a randomized, double-blind, parallel-group study comparing
the anti-anginal and anti-ischaemic effects of ivabradine with placebo
when given to patients with chronic stable angina pectoris receiving
the beta-blocker atenolol. The study consisted of a 6 to 8 week
single-blind run-in period followed by a 4-month, double-blind treat-
ment period (Figure 1). During the run-in period, all patients received
atenolol 50 mg o.d. and placebo b.i.d. and underwent three ETTs. The
ﬁrst ETT took place 2 weeks after the pre-selection visit for patients
already treated with atenolol 50 mg o.d., or 4 weeks after pre-selection
for patients previously treated with another beta-blocker and switched
to atenolol 50 mg o.d. on the day of pre-selection. The second ETT (2
weeks later) and the third ETT (10 days after the second ETT and
designated as baseline, M0; Figure 1) were used to assess stability of
patients’ ETT results. All three ETTs had to be positive (see details
in what follows), and time to 1 mm ST-segment depression had to
be within +20% or +1 min between the second and third ETTs
for patients to be included.
Included patients (i.e. those with positive and stable ETT results
during the run-in period) were randomized to receive ivabradine or
placebo given in combination with atenolol 50 mg o.d. for the entire
double-blind treatment period. The ivabradine dose was 5 mg b.i.d.
for 2 months, with a forced up-titration to 7.5 mg b.i.d. for the ﬁnal
2 months, provided that resting heart rate was not ,50 b.p.m. at
the 2 month (M2) visit. The random allocation schedule was
computer-generated using non-adaptive balanced randomization, stra-
tiﬁed by the centre. An independent organization, Fisher Clinical Ser-
vices, supervised randomization. Study treatment was allocated via an
automated fax system. Ivabradine and placebo tablets were of similar
appearance. Treatment efﬁcacy was evaluated by further ETT at 2
and 4 months of study drug treatment (M2 and M4, respectively;
Figure 1). Patients also kept an anginal symptoms diary, in which the
occurrence of anginal attacks and the consumption of short-acting
nitrates were recorded.
Short-acting nitrates could be taken as required, but not within 3 h
before the ETT. Other drugs that could interfere with the natural
course of angina pectoris (long-acting nitrates, calcium antagonists,
other beta-blockers, potassium channel openers, molsidomine, trime-
tazidine) or the interpretation of ST-segment changes (anti-arrhythmic
agents, digitalis, monoamine oxidase inhibitors) were not allowed
during the trial. Drugs with known or suspected interactions with ivab-
radine (antifungal azole derivatives, macrolide antibiotics, cyclosporine,
antiprotease agents) or atenolol (ﬂoctafenine, sultopride, clonidine,
reserpine, guanethidine, meﬂoquine, anticholinesterase agents) were
also not allowed.
The study was registered on the ClinicalTrials.gov website (identiﬁer
NCT00202566).
Exercise tolerance testing
Symptom-limited treadmill ETTs, using the standard Bruce protocol,
were performed in the morning at approximately the same time of
day on each visit. Patients did not take their morning dose of study
treatment before ETT, so that tests were performed at the trough
of drug activity for both the study drug and the background treatment,
12 h after the last intake of ivabradine and 24 h after the last intake of
atenolol.
Time to onset of angina and time to limiting angina during ETT were
determined by the investigator, whereas total exercise duration and
time to 1 mm ST-segment depression were determined by central
reading. Heart rate was obtained from the ECG recording, and
rate–pressure product (heart rate   systolic blood pressure) at rest
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ments made by the investigator.
During the run-in period, ETTs were considered positive if stopped
owing to the occurrence of limiting angina pectoris accompanied by at
least 1 mm ST-segment depression between 3 and 12 min of exercise.
During the treatment period (i.e. at M2 and M4), ETT could continue
beyond 12 min or stop before 3 min, and stopping criteria included
limiting angina pectoris, dyspnoea, and extreme fatigue. The
ST-segment was measured 80 ms after the J-point in three consecutive
QRS complexes with a ﬂat baseline. If ST-segment depression was
present at rest, the change was calculated from the value at rest to
the value during exercise. If ST-segment elevation was present at
rest, ST depression during exercise was calculated from the ECG
isoelectric line. Thus, time to 1 mm ST-segment depression was
calculated as the time to 1 mm ST-segment depression in the case
of an isoelectric or elevated ST-segment at rest, and as the time to a
further 1 mm depression in the case of ST depression at rest.
During study drug treatment, if 1 mm ST-segment depression or
angina did not occur during the ETT, total exercise duration was
used as the measure of time to 1 mm ST-segment depression and
time to onset of angina.
ETT and ECG tracings were analysed centrally at a reading centre by
cardiologists blinded to treatment allocation. When reading the M2
and M4 ETT tracings during study drug treatment, the cardiologist
did not have access to previous ETT data.
Endpoints
The primary efﬁcacy endpoint was the change in total exercise duration
from baseline (M0) to end of treatment (M4), measured during ETT at
the trough of ivabradine activity in the full analysis set, deﬁned as all
randomized patients who took one or more doses of study medication
and had one or more evaluations of the main efﬁcacy endpoint.
Secondary efﬁcacy endpoints included changes from baseline to M4 in
other ETT criteria, heart rate and rate–pressure product at rest and
at peak of exercise, and changes from baseline to M2 in all ETTs,
heart rate, and rate–pressure product criteria. Changes in anginal
attack frequency and short-acting nitrate consumption recorded in
patients’ diaries were also analysed as secondary efﬁcacy criteria.
Statistical analysis
The sample size was calculated to demonstrate the superiority of ivab-
radine compared with placebo in the primary efﬁcacy endpoint. For a
standard deviation of 110 s, 350 patients per group were necessary to
detect a  30 s difference with 95% power and a one-sided type I error
of 2.5%. Assuming withdrawal of 5% of patients after randomization,
approximately 750 patients would have to be included in the study.
Data are presented as mean values+SD, and 95% conﬁdence inter-
vals (two-sided) are given as appropriate. The main analysis of ETT cri-
teria was performed on an intention-to-treat basis in the full analysis
set, and the last non-missing value observed over a 4-month treatment
period has been considered in the analyses. Groups were compared
using a parametric covariance analysis adjusted for country factor
and baseline value as covariate. The type I error was set at 2.5% (one-
sided). Sensitivity analyses were also performed using a parametric
analysis of variance without adjustment, and a non-parametric covari-
ance analysis based on Wilcoxon rank norm
14 with adjustment. For the
frequency of anginal attacks and consumption of short-acting nitrates,
95% conﬁdence intervals were calculated using a parametric analysis of
variance without adjustment, and a non-parametric approach without
adjustment based on the Hodges–Lehmann’s estimator
15 was used as
sensitivity analysis. Safety analyses were performed on all patients who
received one or more doses of study drug.
Figure 1 Summary of study design.
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Patient characteristics
In all, 889 patients from 219 centres in 20 countries were ran-
domized to the ivabradine (n ¼ 449) and placebo (n ¼ 440)
groups between August 2005 and June 2007. The full analysis
set consisted of 875 patients (98% of those randomized), and
the disposition of patients throughout the study including the
run-in period is shown in Figure 2. A total of 26 patients withdrew
early from study medications, 18 (4%) in the ivabradine group and
8 (2%) in the placebo group. In the ivabradine group, 393 patients
(90%) had their dose up-titrated from 5 to 7.5 mg b.i.d. after 2
months of treatment.
The mean age of patients was approximately 60 years,
84% were male, 94% were Caucasian, and the majority (69%)
was in Canadian Cardiovascular Society angina class II at
baseline (Table 1). Clinical and ETT characteristics at baseline
were similar between patients randomized to the ivabradine
and placebo groups. Randomized patients showed good
stability of ETT results between the second and third (M0)
ETTs during the run-in period: mean total exercise duration
differed by only 5 s between the second (444+107 s)
and third (448+106 s) run-in ETTs. All patients but three
were in sinus rhythm at inclusion on centrally analysed ECG
tracings.
Efﬁcacy
The primary efﬁcacy criterion, change in total exercise duration at
M4 in the full analysis set, increased by 24.3+65.3 s in the ivabra-
dine group compared with 7.7+63.8 s in the placebo group (P ,
0.001). More patients experienced an improvement in TED of
.30 s in the ivabradine group (48%) than in the placebo group
(34%, P , 0.001). There were also improvements with ivabradine
treatment, relative to placebo, in all other ETT criteria at M4
(P , 0.001 for all; Table 2, Figure 3).
Improvements in all ETT criteria, relative to placebo, were also
seen in the ivabradine group at 2 months of therapy with ivabra-
dine 5 mg b.i.d., (M2; Table 3) although the changes were larger
at the end of the study and with higher doses.
Ivabradine treatment produced dose-dependent reductions in
heart rate and rate–pressure product, both at rest and at the peak
of exercise at M4 (Table 4). Corresponding reductions were also
seen at M2, with further reduction at M4 in each case (Table 5).
The frequency of angina attacks decreased signiﬁcantly from baseline
to M4 in both treatment groups, from 1.8+3.3 to 0.9+2.4 attacks/
week in the ivabradine group, and from 1.6+2.4 to 0.9+2.1
attacks/week with placebo (between-group difference not signiﬁ-
cant). Among symptomatic patients [here deﬁned as those who
experienced one or more angina attacks during the run-in period,
n ¼ 625 (70%)], angina attack frequency was reduced by 1.3
attacks/week (relative change 252%) with ivabradine and by 1.0
Figure 2 Disposition of patients throughout the study. AE, adverse event; ETT, exercise tolerance test.
Efﬁcacy of ivabradine 543attack/week (relative change 246%) with placebo (between-group
difference not signiﬁcant).
Safety
Ivabradine was well tolerated in the study: the numbers of patients
withdrawn from treatment owing to emergent adverse events
were 13 (2.9%) in the ivabradine group and 4 (0.9%) with
placebo (difference not signiﬁcant). Among these emergent
adverse events, there were ﬁve serious in the ivabradine group
(1.1%) and three in the placebo group (0.7%). The most frequent
causes of withdrawal related to bradycardia [ivabradine ﬁve
patients (1.1%), placebo none] and unstable or aggravated angina
pectoris [ivabradine three patients (0.7%), placebo one (0.2%)].
The most frequent emergent adverse events were those related
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Table 1 Baseline clinical and exercise tolerance test
characteristics of randomized patients
Ivabradine
(n ¼ 449)
Placebo
(n ¼ 440)
P-value
Age, years 59.6+7.6 60.1+8.0 0.30
Male, n (%) 380 (84.6) 370 (84.1) 0.82
Smoker (including
ex-smoker), n (%)
271 (60.4) 250 (56.8) 0.28
CCS angina class, I/II/III,% 21.2/67.0/11.8 17.7/70.2/12.0 0.43
Previous MI, n (%) 225 (50.1) 226 (51.4) 0.71
Previous PCI, n (%) 95 (21.2) 89 (20.2) 0.49
Previous CABG, n (%) 135 (30.1) 123 (28.0) 0.73
Diabetes mellitus, n (%) 97 (21.6) 96 (21.8) 0.94
Concomitant treatments at inclusion
Acetylsalicylic acid, n
(%)
369 (82.2) 373 (84.8) 0.30
Statins, n (%) 341 (75.9) 330 (75.0) 0.74
ACE-inhibitors, n (%) 235 (52.3) 252 (57.3) 0.21
Supine BP (mmHg)
systolic
127.3+12.0 127.6+12.6 0.67
Supine BP (mmHg)
diastolic
78.6+7.4 78.1+7.2 0.27
Heart rate at rest (b.p.m.)
Mean+SD 66.9+6.9 67.2+6.9 0.57
Min–max 41–99 53–107
Total exercise duration (s)
Mean+SD 445.1+105.5 451.1+107.4 0.40
Min–max 224–716 221–720
Time to limiting angina (s)
Mean+SD 441.4+105.6 446.7+107.2 0.46
Min–max 223–716 216–715
Time to angina onset (s)
Mean+SD 351.3+104.5 357.0+104.5 0.42
Min–max 129–659 81–674
Time to 1 mm ST-segment depression (s)
Mean+SD 338.1+97.2 347.1+103.4 0.18
Min–max 185–655 185–715
Heart rate at peak exercise (b.p.m.)
Mean+SD 128.6+16.9 129.9+18.0 0.29
Min–max 82–179 75–179
RPP at rest (b.p.m.   mmHg)
Mean+SD 9389+1661 9427+1830 0.75
Min–max 5800–15 200 4500–20 320
RPP at peak exercise (b.p.m.   mmHg)
Mean+SD 21 110+4300 21 249+4566 0.64
Min–max 10 660–36 800 10 500–34 500
Mean values+standard deviation unless otherwise stated. BP, blood pressure;
CABG, coronary artery bypass graft; CCS, Canadian Cardiovascular Society
classiﬁcation; MI, myocardial infarction; PCI, percutaneous coronary intervention;
RPP, rate–pressure product.
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Table 2 Changes in exercise tolerance test criteria
between baseline and end of study (M4) in the full
analysis set
Ivabradine (n ¼ 441) Placebo (n ¼ 434)
Total exercise duration (s)
Baseline 445.6+105.6 450.7+107.5
End of study 469.9+119.2 458.4+111.1
Change 24.3+65.3 7.7+63.8
Difference
a (SE) 16.3 (4.3)
95% CI 7.9–24.7
P-value
b ,0.001
Time to limiting angina (s)
Baseline 441.9+105.7 446.6+107.4
End of study 467.9+119.8 456.0+111.1
Change 26.0+65.7 9.4+63.8
Difference
a (SE) 16.3 (4.3)
95% CI 7.9–24.7
P-value
b ,0.001
Time to angina onset (s)
Baseline 352.5+104.6 357.2+104.8
End of study 401.6+125.5 379.9+115.8
Change 49.1+83.3 22.7+79.1
Difference
a (SE) 25.5 (5.4)
95% CI 15.0–36.0
P-value
b ,0.001
Time to 1 mm ST depression (s)
Baseline 337.8+97.2 347.2+104.0
End of study 383.5+123.2 362.6+122.5
Change 45.7+93.0 15.4+86.6
Difference
a (SE) 28.5 (6.0)
95% CI 16.8–40.3
P-value
b ,0.001
Mean values+standard deviation unless otherwise stated. CI, conﬁdence interval;
SE, standard error.
aIvabradine minus placebo, estimate from parametric approach adjusted on
baseline and country factors.
bStudent’s t-test for superiority.
J.-C. Tardif et al. 544to bradycardia, reported by 19 patients (4.2%) in the ivabradine
group (12 patients with ivabradine 5 mg b.i.d. and 7 with ivabradine
7.5 mg b.i.d.) and 2 patients (0.5%) with placebo. Only 1.1% of
adverse events related to bradycardia were symptomatic. Phos-
phenes (luminous phenomena described as increases in brightness
in limited areas of the visual ﬁeld) and blurred vision, which
have been associated with ivabradine treatment in previous
studies,
11–13 were reported by nine patients (2%) in the ivabradine
group and four (0.9%) in the placebo group. There were small,
non-signiﬁcant changes in supine blood pressure from baseline to
the last value on treatment (from 127.3+12.0 to 128.3+
14.8 mmHg for systolic blood pressure and from 78.6+7.4 to
78.1+8.0 mmHg for diastolic blood pressure with ivabradine,
and from 127.6+12.6 to 126.1+14.8 and 78.1+7.2 to
78.1+7.5 mmHg, respectively, with placebo). There was one
death during the treatment period, a fatal suicide in the ivabradine
group and two deaths after the last study drug intake in the
placebo group.
Discussion
The main ﬁnding from this study is that long-term heart rate
reduction by ivabradine produced a signiﬁcant improvement rela-
tive to placebo in the primary efﬁcacy criterion, total exercise dur-
ation at the trough of drug activity at 4 months of treatment, in
patients with chronic stable angina pectoris receiving the beta-
blocker atenolol. There were also signiﬁcant improvements with
ivabradine in all ETT criteria at 2 months of treatment, with
further improvement at 4 months after forced up-titration of the
ivabradine dose from 5 to 7.5 mg b.i.d. These improvements in
exercise capacity were accompanied by reductions in heart rate
and rate–pressure product at rest and at the peak of exercise,
which also were signiﬁcant at 2 months and larger at 4 months.
The primary efﬁcacy endpoint used in the present study, total
exercise duration in standardized ETT at the trough of drug
activity, is the one speciﬁed in current European guidelines.
16
The dose of atenolol used as background therapy throughout
the study was 50 mg per day. This reﬂects general clinical practice,
and was the median atenolol dose in a recent population study of
beta-blocker use in patients after an acute myocardial infarction.
17
In spite of recommendation to titrate beta-blockers to full dosages,
data in clinical practice reveal substantial underdosing of all beta-
blockers, with dosages generally  50% than the dosages that ran-
domized trials have proved to be effective.
17 This could in part be
related to reduced tolerability of higher doses of beta-blockers
because of fatigue, depression, bronchospasm, or erectile dysfunc-
tion. Thus in patients who cannot be given higher doses of beta-
blockers or in whom sufﬁcient heart rate reduction cannot be
achieved, the combination with ivabradine appears to be an appro-
priate therapeutic option.
Combination therapy is widely used in clinical practice in order to
achieve adequate control of angina. In the Euro Heart Survey of the
initial management of stable angina pectoris, the majority (59%) of
patients were on two or more anti-anginal drugs. Among patients
scheduled to be managed by medical therapy alone, the proportion
was even higher at 80%.
8 However, clinical trials evaluating combi-
nation therapy have yielded inconsistent results. Most studies have
been small and many have not shown signiﬁcant beneﬁts of combi-
nations as opposed to single-drug therapy. For example, the TIBET
study, one of the largest studies of combination therapy, compared
atenolol with slow-release nifedipine given alone and in combination,
and showed no signiﬁcant beneﬁt of combination therapy for any
Figure 3 Changes in exercise tolerance test criteria between baseline and M2 visit and between baseline and end of study (M4) in the full
analysis set.
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18 Similarly, studies of amlodipine or diltiazem on top
of atenolol
19 and the combination of amlodipine and atenolol
20
showed no additional improvement in ETT criteria by adding a
second drug to atenolol. A meta-analysis of randomized studies
comparing the addition of a calcium antagonist to beta-blocker
therapy and vice versa found small but signiﬁcant beneﬁts of
combination therapy at the peak of activity of the added drug, but
no signiﬁcant improvements at the trough of activity.
21 A recent
positive trial of combination therapy involved the metabolic agent
ranolazine given on top of atenolol (50 mg/day), amlodipine (5 mg/
day), or diltiazem (180 mg/day) in patients with severe angina
pectoris. The combination showed an improvement in total exercise
duration, although changes in time to 1 mm ST-segment depression
were not signiﬁcant.
22 The present study, in terms of the size of
the trial, the compliance with regulatory recommendations, and
the consistency of signiﬁcant improvements across all ETT criteria
and time points, represents perhaps the most compelling single
demonstration of the beneﬁt of any combination of anti-anginal
drugs published to date.
In the present study, treadmill ETTs were performed using the
standard Bruce protocol, in which higher workloads are reached
more rapidly than in the modiﬁed Bruce protocol.
23 The more
demanding standard Bruce protocol was chosen in view of the
fact that patients were receiving background therapy known to
improve exercise capacity. At baseline, resting heart rate was
67 b.p.m. and mean angina attack frequency was only 1.6–1.8
attacks per week, compared with approximately 3.3 attacks per
week in the published INITIATIVE study of ivabradine vs. atenolol
in 939 patients with stable angina pectoris.
12 In the current study,
264 patients (30%) recorded no angina attacks during the run-in
period on background therapy alone. The low mean number of
angina attacks at baseline may explain that we did not reach stat-
istical signiﬁcance for the reduction of angina attacks. The improve-
ments in total exercise duration in the present study (on top of
background beta-blockade) were numerically smaller than in the
previous INITIATIVE study of ivabradine monotherapy
12 that
used the modiﬁed Bruce ETT protocol. Nevertheless, the
additional 16.3 s in total exercise duration with ivabradine treat-
ment in the present study, relative to placebo, was, on average,
achieved at a walking speed of 5.5 km/h up a gradient of 14%.
This represents a substantial additional workload in this context.
Ivabradine in combination with beta-blocker therapy was well
tolerated in this study. Adverse events related to low heart rate
are predictable with any heart rate-lowering therapy, and the
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Table 3 Changes in exercise tolerance test criteria
between baseline and M2 visit in the full analysis set
Ivabradine (n ¼ 441) Placebo (n ¼ 434)
Total exercise duration (s)
Baseline 445.6+105.6 450.7+107.1
Change 15.5+60.0 6.8+56.5
Difference
a (SE) 8.2 (3.9)
95% CI 0.6–15.7
P-value
b 0.017
Time to limiting angina (s)
Baseline 441.9+105.7 446.6+107.4
Change 17.0+60.7 8.2+56.8
Difference
a (SE) 8.2 (3.9)
95% CI 0.6–15.8
P-value
b 0.018
Time to angina onset (s)
Baseline 352.5+104.6 357.2+104.8
Change 30.2+72.2 17.2+72.3
Difference
a (SE) 12.3 (4.8)
95% CI 2.9–21.7
P-value
b 0.005
Time to 1 mm ST depression (s)
Baseline 337.4+97.6 347.3+103.8
Change 35.0+84.1 7.8+82.6
Difference
a (SE) 25.3 (5.6)
95% CI 14.4–36.3
P-value
b ,0.001
Mean values+standard deviation unless otherwise stated. CI, conﬁdence interval;
SE, standard error.
aIvabradine minus placebo, estimate from parametric approach adjusted on
baseline and country factors.
bStudent’s t-test for superiority.
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Table 4 Changes in heart rate and rate–pressure
product between baseline and end of study (M4)
Ivabradine (n ¼ 431) Placebo (n ¼ 432)
Heart rate at rest (b.p.m.)
Baseline 67.0+6.8 67.2+6.9
Change 28.7+9.8 21.4+9.8
Difference
a (SE) 27.4 (0.6)
95% CI 28.7 to 26.2
Heart rate at peak exercise (b.p.m.)
Baseline 128.6+16.9 130.1+17.9
Change 211.3+13.2 20.9+12.3
Difference
a (SE) 210.8 (0.8)
95% CI 212.4 to 29.1
RPP at rest (b.p.m.   mmHg)
Baseline 9403+1662 9429+1830
Change 21269+1655 2360+1622
Difference
a (SE) 2920 (99)
95% CI 21115 to 2725
RPP at peak exercise (b.p.m.   mmHg)
Baseline 21 125+4287 21 288+4552
Change 21630+3474 266+3447
Difference
a (SE) 21612 (219)
95% CI 22041 to 21183
Mean values+standard deviation unless otherwise stated. CI, conﬁdence interval;
SE, standard error; RPP, rate–pressure product.
aIvabradine minus placebo, estimate from parametric approach adjusted on
baseline and country factors.
J.-C. Tardif et al. 546low rate of withdrawal for this cause (1.1% in the ivabradine group)
is notable, especially in the light of the low heart rate criterion
( 50 b.p.m.) for up-titration of the study drug. Visual symptoms,
typically phosphenes, are thought to be related to the pharmaco-
logical action of ivabradine on ion channels in the retina that are
similar to those responsible for the If current in the sino-atrial
node. Visual symptoms with ivabradine are typically mild and tran-
sient, without impact on daily activity of the patient. The incidence
of adverse events related to visual symptoms with ivabradine (2.0%
compared with 0.9% in the placebo group) was markedly lower
than in previous studies.
11,12 In these previous studies, patients
were speciﬁcally asked about visual symptoms at study visits. In
the present study, patients were informed of the possibility of
visual symptoms before study commencement, but were not
speciﬁcally asked about them during visits.
Ivabradine directly and selectively inhibits the ionic channel in
the sino-atrial node responsible for If, a current that is important
in pacemaker activity and the physiological regulation of heart
rate.
10,24,25 At therapeutic concentrations, ivabradine has no action
at other cardiac ion channels or receptors and does not act via
altering intracellular cyclic adenosine monophosphate levels. Conse-
quently, ivabradine does not depress myocardial contractility
26,27 or
intracardiac conduction
28 and has only minor effects on blood
pressure as seen in this and previous studies.
12 Thus, the unique
haemodynamic proﬁle of ivabradine can provide anti-ischaemic
efﬁcacy in addition to heart rate lowering with beta-blocker
therapy, and this combination therefore represents a potential
therapeutic strategy to treat patients with stable angina.
In conclusion, ivabradine treatment resulted in signiﬁcant dose-
dependent improvements in all ETT criteria relative to placebo in
patients with stable angina pectoris receiving background therapy
with atenolol. The starting dose of ivabradine was 5 mg b.i.d.,
which was increased at 2 months to 7.5 mg b.i.d. for a further 2
months. Improvements in all ETT criteria were signiﬁcant at 2
months as well as at 4 months, indicating the efﬁcacy of both ivab-
radine doses. The combination of ivabradine and atenolol was well
tolerated, and the incidence of adverse events related to visual
symptoms was markedly lower than reported in previous ivabra-
dine studies. Thus, the combination of ivabradine 7.5 mg b.i.d.
and atenolol at the commonly used dosage in clinical practice in
patients with chronic stable angina pectoris produced additional
efﬁcacy with no untoward effect on safety or tolerability.
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Table 5 Changes in heart rate and rate–pressure
product between baseline and M2
Ivabradine (n ¼ 449) Placebo (n ¼ 440)
Heart rate at rest (b.p.m.)
Baseline 67.0+6.9 67.2+6.9
Change 26.9+9.7 21.1+10.2
Difference
a (SE) 26.0 (0.7)
95% CI 27.2 to 24.7
Heart rate at peak exercise (b.p.m.)
Baseline 128.6+16.9 130.1+17.9
Change 28.9+11.7 0.1+11.0
Difference
a (SE) 29.2 (0.7)
95% CI 210.7 to 27.8
RPP at rest (b.p.m.   mmHg)
Baseline 9403+1662 9433+1830
Change 21163+1613 2354+1593
Difference
a (SE) 2822 (97)
95% CI 21012 to 2632
RPP at peak exercise (b.p.m.   mmHg)
Baseline 21 125+4287 21 288+4552
Change 21439+3436 210+2972
Difference
a (SE) 21482 (204)
95% CI 21882 to 21082
Mean values+standard deviation unless otherwise stated. CI, conﬁdence interval;
SE, standard error; RPP, rate–pressure product.
aIvabradine minus placebo, estimate from parametric approach adjusted on
baseline and country factors.
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